Berberine: The Natural Metformin of Oncology

Targeting AMPK, mTOR, cancer stem cells, and the tumor microenvironment.

Unlike conventional anticancer drugs that target a single molecular pathway, berberine appears to exert broad anticancer effects through simultaneous modulation of metabolism, inflammation, mitochondrial function, cancer stem cells, the tumor microenvironment (TME), and immune signaling. Experimental studies have demonstrated activity across a wide range of malignancies, while early human studies suggest a role in cancer prevention and as an adjunct to standard therapies.

Why Berberine Is Different

One of the major challenges in oncology is the remarkable adaptability of cancer cells. Tumors frequently escape therapies directed at a single target by activating alternative survival pathways.

Berberine is unusual because it influences numerous interconnected pathways simultaneously, including:

• AMPK activation

• mTOR inhibition

• NF-κB suppression

• STAT3 inhibition

• PI3K/AKT signaling

• Wnt/β-catenin signaling

• EGFR signaling

• Mitochondrial metabolism

• Cancer stem cells

• Tumor-associated inflammation

• Gut microbiome regulation

This multi-target profile aligns well with the metabolic theory of cancer, which views cancer as a systems disease involving disturbed cellular energetics rather than simply a collection of genetic mutations.

Anticancer pathways and mechanisms

Berberine’s anticancer mechanisms include reducing the growth of cancer cells, preventing metastasis, inducing apoptosis, activating autophagy, controlling the microbiota in the gut, and enhancing the effects of other cancer treatments by focusing on antibacterial action, which includes controlling the microbiota in the gut and preventing intratumoral microbes. (1-5)

Perhaps the most important anticancer action of berberine is its effect on cellular metabolism. Berberine activates AMP-activated protein kinase (AMPK), often referred to as the cell’s “energy sensor.” AMPK activation suppresses anabolic processes and inhibits mTOR, one of the master regulators of cancer growth and proliferation.

The result is:

• Reduced protein synthesis

• Reduced cellular proliferation

• Increased metabolic stress

• Reduced tumor growth signaling

In many respects, berberine acts similarly to metformin, although it also possesses additional anti-inflammatory and microbiome-modulating effects.

Berberine induces apoptosis in many cancer cell lines by activating caspases, modulating Bcl-2 family proteins, and engaging p53- and AMPK-related pathways.(6) Berberine causes cell-cycle arrest (often at G1 or G2/M), thereby inhibiting DNA synthesis and proliferation in breast, colon, cervical, oral, nasopharyngeal and other cancer cells.(7) Affects key signaling pathways frequently dysregulated in cancer, including Akt/mTOR, MAPK, NF‑κB, EGFR, JAK‑STAT, Wnt/β‑catenin and PARP1, which collectively reduce survival signaling and inflammatory drive in tumors.(8)

Berberine may prevent the growth of cancer cells through the upregulation of miR-214-3p, the downregulation of SCT protein levels, the regulation of catenin, the inhibition of telomerase activity, and the deactivation of MAPK signaling pathways. (9-11) By increasing p21, p27, and p38 and lowering CDK1, CDK4, cyclin A, and cyclin D1, berberine may inhibit the growth of cancer cells. (1, 12) Through the AMPK-p53, PI3K/AKT/mTOR, miR19a/TF/MAPK signaling pathways, and modulation of the CASC2/ AUF1/B-cell/Bcl-2 axis, berberine promotes cancer cells apoptosis.(3, 13-15) Berberine downregulates many TME-related genes, including PDGFRB, COL1A2, and BMP7, and upregulating E-cadherin, thereby inhibiting metastatic spread. (16-18)

Berberine inhibits invasion, metastasis and angiogenesis by downregulating MMP-2/MMP-9, TGF-β1, and pro‑angiogenic signaling, and by modulating microRNAs involved in motility and adhesion.(19)

Berberine modulates tumor microenvironment via anti‑inflammatory and antioxidant effects, immunomodulation, and interference with cancer cell energy metabolism and mitochondrial function.(20)

Berberine has anticancer effects by influencing gut microbiota. For example, berberine increases the Firmicutes/Bacteroidetes ratio and the relative abundance of Clostridiales, Lactobacillaceae, Bacteroides, and Akkermansia muciniphila. (4, 5)

Reviews highlight its potential to overcome multidrug resistance by inhibiting drug efflux pumps and altering expression of multidrug resistance genes. (21) Berberine increases radiation sensitivity and enhances the effects of anticancer medications such as cisplatin, 5-fluorouracil, doxorubicin, niraparib, and icotinib. (22-25)

Synergy with Chemotherapy and Radiation

Another attractive feature of berberine is its apparent ability to enhance the effectiveness of standard cancer treatments.

Laboratory studies demonstrate synergy with:

• Cisplatin

• 5-fluorouracil

• Doxorubicin

• Niraparib

• Icotinib

Berberine has also been shown to increase radiosensitivity in experimental models. These findings suggest a role for berberine as an adjunct rather than a replacement for conventional treatment.

Clinical studies

While there is limited clinical data on the benefits of berberine, a randomized, double-blind study demonstrated that berberine in a dose of 300 mg twice daily significantly reduced the risk of recurrent colorectal adenomas following polypectomy. (26)

Types of cancers that Berberine may be beneficial for

Berberine shows anticancer effects on various cancers, such as breast, lung, gastric, liver, colorectal, ovarian, cervical, and prostate. (1-3, 9-15, 17, 18, 22-25, 27)

Dosing and cautions

A total daily dose of 1000-1500 mg (take 500 mg two or three times daily or 600 mg twice daily) is suggested. As insulin release is glucose-dependent, hypoglycemia has not been reported with this herb; however, blood glucose should be monitored and the additive/synergistic effect of metformin on the blood glucose profile should be determined. Berberine should not be taken in patients taking cyclosporine as this combination will increase cyclosporine levels (absolute contraindication). Berberine may alter the metabolism of the following drugs, which should be used with caution (monitor effects): anticoagulants, dextromethorphan, tacrolimus (Prograf), phenobarbitone, losartan (inhibits effect) and sedative drugs

(see https://www.webmd.com/vitamins/ai/ingredientmono-1126/berberine).

If you are scheduled for surgery, please notify your anesthesia team if you are taking Berberine. You may need to stop taking Berberine one week prior to surgery.

Depending on the patient’s blood glucose levels, providers can consider using metformin and berberine together or alternating (switching back and forth for one month at a time.

If you’ve found this work valuable, please consider upgrading to a paid subscription. Your support helps me continue independent research and share practical, evolving insights—while giving you access to deeper content and more direct engagement.

If you found this article helpful, please restack it to help others discover the Cancer & Metabolic Healing Playbook.

Medical Disclaimer: The discussion of repurposed medications in this article is intended to review the scientific literature and does not constitute a recommendation for self-treatment. Decisions regarding the use of off-label therapies should be made in consultation with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan. Please see the full Medical Disclaimer on the introductory page to Marik’s Cancer & Metabolic Healing Playbook.

References

1. Xiong RG, Huang SY, Wu SX, Zhou DD, Yang ZJ, Saimaiti A, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: An update review. Molecules. 2022;27:4523.

2. Yao M, Fan X, Yuan B, Takagi N, Liu S, Han X, et al. Berberine inhibits NLRP3 inflammasone pathway in human triple-negative breast cancer MDA-MB-231 cell. BMC Complementary and Alternative Medicine. 2019;19:216.

3. Pan Y, Zhang F, Zhao Y, Shao D, Zheng X, Chen Y, et al. Berberine enhances chemosensitivity and induces apoptosis through dose-orchestrated AMPK signaling in breast cancer. J. Cancer. 2017;8:1679–89.

4. Shu X, Li M, Cao Y, Li C, Zhou W, Ji G, et al. Berberine alleviates non-alcoholic steatohepatitis through modulating gut microbiota mediated intestinal FXR activation. Front. Pharmacol. 2021;12:750826.

5. Li S, Wang N, Tan HY, Chueng F, Zhang ZJ, Yuen MF, et al. Modulation of gut microbiota mediates berberine-induced expansion of immuno-suppressive cells to against alcoholic liver disease. Clinical and Translational Medicine. 2020;10:e112.

6. Almatroodi SA, Alsahli MA, Rahmani AH. Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways. Molecules. 2022;27(18).

7. Li Q, Zhao H, Chen W, Huang P. Berberine induces apoptosis and arrests the cell cycle in multiple cancer cell lines. Arch Med Sci. 2023;19(5):1530–7.

8. Sajeev A, Sailo B, Unnikrishnan J, Talukdar A, Alqahtani MS, Abbas M, et al. Unlocking the potential of Berberine: Advancing cancer therapy through chemosensitization and combination treatments. Cancer Lett. 2024;597:217019.

9. Zhu C, Li J, Hua Y, Wang J, Wang K, Sun J. Berberine inhibits the expression of SCT through miR-214-3p stimulation in breast cancer cells. Evidence-Based Complementary and Alternative Medicine. 2020;2020:2817147.

10. Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian Y, et al. Berberine binds RXRalpha to suppress Beta-catenin signaling in colon cancer cells. Oncogene. 2017;36:6906–18.

11. Samad MA, Saiman MZ, Majid NA, Karsani SA, Yaacob JS. Berberine inhibits telomerase activity and induces cell cycle arrest and telomere erosion in colorectal cancer cell line, HCT 116. Molecules. 2021;26:376.

12. Zhao Z, Zeng J, Guo Q, Pu K, Yang Y, Chen N, et al. Berberine suppresses stemness and tumorigenicity of colorectal cancer stem-like cells by inhibiting m6 A methylation. Front. Oncol. 2021;11:775418.

13. Chen QQ, Shi JM, Ding Z, Xia Q, Zheng TS, Ren YB, et al. Berberine induces apoptosis in non-small-cell lung cancer cells by upregulating miR-19a targeting tissue factor. Cancer Management and Research. 2019;11:9005–15.

14. Kou Y, Tong B, Wu W, Liao X, Zhao M. Berberine improves chemo-sensitivity to cisplatin by enhancing cell apoptosis and repressing PI3K/AKT/mTOR signaling pathway in gastric cancer. Front. Pharmacol. 2020;11:616251.

15. Dai W, Mu L, Cui Y, Li Y, Chen P, Xie H, et al. Berberine promotes apoptosis of colorectal cancer via regulation of the long non-coding RNA (IncRNA) cancer susceptibility candidate 2 (CASC2)/AU-biding factor 1 (AUF1)/Bcell CLL/Lymphoma 2 (Bcl-2) axis. Med. Sci. Monit. 2019;25:730–8.

16. Jeong Y, You D, Kang HG, Yu J, Kim SW, Nam SJ, et al. Berberine suppresses fibronectin expression through inhibition of c-jun phosphorylation in breast cancer cells. J. Breast Cancer. 2018;21:21–7.

17. Chu SC, Yu CC, Hsu LS, Chen KS, Su MY, Chen PN. Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol. Pharmacol. 2014;86:609–23.

18. Liu CH, Tang WC, Sia P, Huang CC, Yang PM, Wu MH, et al. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesechchymal transition (EMT) associated genes with predictive and prognostic relevance. Int. J. Med. Sci. 2015;12:63–71.

19. Guo P, Cai C, Wu X, Fan X, Huang W, Zhou J, et al. An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology. Front Pharmacol. 2019;10:857.

20. Wang Y, Liu Y, Du X, Ma H, Yao J. The Anti-Cancer Mechanisms of Berberine: A Review. Cancer Manag Res. 2020;12:695–702.

21. Zhang C, Sheng J, Li G, Zhao L, Wang Y, Yang W, et al. Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Front Pharmacol. 2019;10:1461.

22. Chen Y, Zhang H. Berberine and chemotherapeutic drugs synergistically inhibits cell proliferaion and migration of breast cancer cells. Int. J. Clin. Exp. Med. 2018;11:13243–50.

23. Zhao Y, Jing Z, Li Y, Mao W. Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis. Oncology Reports. 2016;36:567–72.

24. Chen P, Dai CH, Shi ZH, Wang Y, Wu JN, Chen K, et al. Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis. Apoptosis. 2021;26:639–56.

25. You HY, Xie XM, Zhang WJ, Zhu HL, Jiang FZ. Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203. In Vitro Cellular & Developmental Biology - Animal. 2016;52:857–63.

26. Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol. Hepatol. 2020;5(3):267–75.

27. Zhang Q, Wang X, Cao S, Sun Y, He X, Jiang B, et al. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Biomedicine and Pharmacotherapy. 2020;128:110245.